secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
CIK:        0001500198
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001213900-25-076039
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroOne Q3 revenue up 105% to $1.7M; net loss narrows to $1.5M; FY25 guidance reaffirmed
--------------------------------------------------------------------------------

- Product revenue $1.7M, up 105% YoY; gross margin 53.9% (vs 34.1%).
- Net loss $1.5M ($0.03 EPS) vs $2.8M ($0.10 EPS); operating expenses down 9% to $2.8M.
- Oversubscribed $8.2M capital raise closed April 2025; cash $8.0M, no debt.
- FY2025 product revenue guidance $8-10M (132-190% growth); gross margin guidance raised to 50-53%.
- Milestones: FDA 510(k) filed for trigeminal ablation; first patient seizure-free 1-year; sEEG drug delivery order.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1500198/000121390025076039/0001213900-25-076039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1500198/000121390025076039/ea0252735-8k_neuroone.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-076039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer